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Abstract
Background: Platinum-based systemic chemotherapy is the treatment of choice for patients with advanced
urothelial carcinoma (UC). Although no chemotherapeutic regimen is established as a second-line therapy, recent
studies reported that methotrexate, vinblastine, Adriamycin and cisplatin (MVAC) elicited a significant response in
patients who failed gemcitabine and platinum (GP) chemotherapy. We investigated the clinical factors useful for
predicting a favourable response to MVAC in UC patients who failed GP.
Methods: Forty-five patients with advanced UC who received second-line MVAC chemotherapy after failure with
first-line GP chemotherapy were enrolled in this study. Univariate and multivariate analyses based on Cox’s
regression were performed to identify independent prognostic factors for progression-free survival (PFS) after
second-line MVAC chemotherapy.
Results: The median follow-up period after the first MVAC administration was 10.0 months. The median PFS and
overall survival (OS) were 6.5 months (95 % confidence interval [CI]: 5.1–7.9) and 14.5 months (95 % CI, 7.4–21.4),
respectively. The overall response rate was 57.8 %. The response to first-line GP chemotherapy (hazard ratio [HR],
2.500; p = 0.012) and patient age (HR, 1.047; p = 0.033) were predictors of PFS after MVAC chemotherapy.
Conclusions: The response to first-line GP chemotherapy and age were independent predictors of PFS in patients
who received second-line MVAC chemotherapy. This report is the first to describe independent predictors of PFS
after MVAC chemotherapy.
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Background
Systemic chemotherapy is the treatment of choice for
metastatic, recurrent or inoperable urothelial carcinoma
(UC). Methotrexate, vinblastine, Adriamycin and cis-
platin (MVAC) chemotherapy was used worldwide as
the standard treatment since the first report of its
efficacy in 1985 [1]. However, since gemcitabine and
cisplatin (GC) chemotherapy showed similar efficacy
as MVAC but with less toxicity in a large, randomized,
multinational and multicentre phase III study of GC
combination chemotherapy, [2] GC regimens are now
used mostly as the initial systemic chemotherapy for UC.
GC chemotherapy has an excellent response rate in
patients with advanced UC, and up to 20 % of individuals
have achieved a complete response of long-term, disease-
free survival [3]. However, most patients eventually experi-
ence disease progression or relapse after GC. Several regi-
mens have been investigated in the second-line setting
after the failure of GC, including taxanes, vinflunine, ifos-
famide, ixabepilone and pemetrexed; [4–9] however, no
regimen has yet achieved a competent survival benefit in
the second-line setting.
Recently, a small number of clinical trials proposed that
platinum-based regimens are effective in a significant
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portion of patients in whom platinum-based chemother-
apy initially failed when the regimen was based on cis-
platin but using different agents in the second-line setting.
The efficacy and safety of MVAC chemotherapy as a
second-line treatment after the failure of gemcitabine and
platinum (GP) chemotherapy has been reported in several
small-scale studies [10–13]. However, there is a lack of
predictive factors available for the personalized selection
of chemotherapeutic regimens in patients with UC. There-
fore, we investigated the factors predictive of a favourable
response to second-line MVAC chemotherapy after GP in
patients with advanced UC to facilitate the development
of a tailored second-line treatment strategy. Here, we
investigated the predictive value of the response to
first-line GP chemotherapy for selecting suitable can-
didates for the MVAC regimen as the second-line
chemotherapy in patients with advanced UC.
Methods
Study population
The medical ethics committee of Severance Hospital,
Yonsei University Health Care System (Seoul, Korea) ap-
proved this retrospective study. Our medical ethics com-
mittee allows exempt of informed consent if the
research uses the collection or study of existing data,
documents and records and these sources are publicly
available and the information is recorded by the investi-
gator in such a manner that subjects cannot be identi-
fied. From these regulations, our study was classified as
exempt from the informed consent requirement because
this study was based on the collection of existing pub-
licly available data, documents and records, and we re-
corded all data in a manner that subjects cannot be
identified. Between July 2004 and August 2014, 64 con-
secutive patients who received MVAC chemotherapy as
the second-line treatment due to the relapse or disease
progression of UC after first-line GP chemotherapy in
the only metastatic setting were included in this study.
Nineteen of the 64 patients were excluded because of
incomplete medical records (seven patients), another
synchronous metastatic malignancy (five patients), an
atypical carcinoma (four patients) or a history of neoad-
juvant chemotherapy (three patients). Forty-five patients
were included in the final analysis.
Treatment
Before starting chemotherapy, all patients were required
to have an Eastern Cooperative Oncology Group (ECOG)
performance status (PS) ≤ 2, adequate hematologic param-
eters (absolute granulocyte count ≥ 1,500/dL, haemoglo-
bin ≥ 8.5 g/dL and a platelet count ≥ 100,000/dL) and
sufficient hepatic (serum bilirubin ≤ 1.5 mg/dL) and renal
(estimated glomerular filtration rate ≥ 50 mL/min) function.
Methotrexate was given at a dose of 30 mg/m2 on days 1,
15 and 22, vinblastin was given at a dose of 3 mg/m2 on
days 2, 15 and 22, Adriamycin was given at a dose of
30 mg/m2 on day 2 and cisplatin was given at a dose of
70 mg/m2 on day 2. The cycles were repeated every 28 days,
and treatment continued until the disease regressed or the
toxicity was intolerable.
Response and toxicity assessment and dose modification
Basically, after the completion of three cycles, imaging
tools (computed tomography scans, radionuclide bone
scans or positron emission tomography) were used to
evaluate the treatment response after three cycles, ex-
cept for cases with symptomatic progression. Perform-
ance status, haematological parameters and liver and
kidney function were measured weekly in each patient
to assess for potential toxicity. The response was evalu-
ated according to the Response Evaluation Criteria for
Solid Tumours, [14] and toxicity was determined using
the National Cancer Institute Common Toxicity Criteria
(ver. 4.0). The platinum dose was reduced by 20–30 % in
patients who experienced grade 4 haematological tox-
icity or grade 3/4 non-haematological toxicity.
Outcomes
The end point of the study was PFS in patients who re-
ceived MVAC chemotherapy. The PFS of patients who
received MVAC chemotherapy was defined as the time
from the date of the beginning of the first MVAC cycle
to the date that progression was identified, death, or loss
to follow-up. Progression was defined as a ≥ 20 %
increase in the overall sum of the diameter of the target
lesions on radiological assessments.
Clinical data and statistical analysis
All included patients were divided into good or poor re-
sponse groups based on the response to the first-line GP
chemotherapy. The good response group included the
complete response (CR) and partial response (PR)
groups to first-line GP chemotherapy, while the poor
response group included the stable disease (SD) and
progression disease (PD) groups [15]. The baseline
characteristics of the two groups were then compared
using Chi-squared tests. PFS after MVAC chemother-
apy was calculated using the Kaplan-Meier method,
and statistical significance was determined using log
rank tests. Age, haematological parameters, liver and
kidney function, serum albumin concentration at the
beginning of the first MVAC and time to progression
(TTP) after first-line GP chemotherapy were included
in the analysis as continuous variables. Clinical nodal
status, distant metastatic status, ECOG PS at the begin-
ning of the first MVAC and response to previous GP
chemotherapy were analysed as categorical variables.
Statistical analyses to identify independent predictors
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of progression after MVAC chemotherapy were per-
formed using univariate and multivariate Cox’s pro-
portional hazard regression analyses. Variables that
were significant in the univariate analysis (p < 0.05)
were entered into the multivariate model. All statis-
tical analyses were performed using SPSS Statistics
version 20.0.0 (IBM Corp., Armonk, NY, USA). For
all analyses, a two-sided p-value <0.05 was considered
to indicate statistical significance.
Results
Patients
The median follow-up period after the first MVAC admin-
istration was 10.0 months. The median PFS and overall
survival (OS) were 6.5 months (95 % confidence interval
[CI] 5.1–7.9) and 14.5 months (95 % CI 7.4–21.4), respect-
ively. The overall response rate was 57.8 %. A CR was
achieved in two patients (4.4 %) and a PR in twenty-four
(53.3 %). The baseline characteristics of the study popula-
tion, including the response to first-line GP chemotherapy,
are presented in Table 1.
Characteristics of good and poor responses to previous
GC chemotherapy
All included patients were divided into two groups:
a good response group and a poor response group,
according to the response to first-line GP chemo-
therapy. The characteristics of the two groups are
presented in Table 2. The median treatment-free in-
tervals (TFI) between GP and MVAC chemotherapies
for the good and poor response groups were 2.5 and
1.7 months, respectively. There were significant dif-
ferences in haemoglobin and serum bilirubin levels
between the two groups, but not in the variable re-
lated to the response to first-line GP chemotherapy
(TTP and the number of cycles of first-line GP chemo-
therapy). The PFS of patients in each of the two groups
was calculated using the Kaplan-Meier method. The me-
dian PFS after second-line MVAC chemotherapy was
8.0 months (95 % CI 5.4–10.7) in the good response group
and 3.7 months (95 % CI 2.6–4.8) in the poor response
group. The results of the log rank test indicated a statisti-
cally significant difference (p = 0.008) in PFS between the
two groups (Fig. 1).
Prognostic predictors of PFS after MVAC chemotherapy
Univariate and multivariate Cox’s regression analyses
were performed to identify the independent predictive
factors of PFS after MVAC chemotherapy. The results of
the univariate and multivariate analyses demonstrated
that age (hazard ratio [HR] = 1.047, p = 0.033) and
response to first-line GC chemotherapy (HR = 2.500,
p = 0.012) were predictors of PFS after MVAC
chemotherapy (Table 3).
Toxicity
Anaemia, neutropenia, and thrombocytopenia ≥ grade 3
developed in 25, 29, and 20 patients, respectively. A
blood transfusion or granulocyte colony-stimulating fac-
tor was administered to patients who experienced severe
haematological complications. Alopecia was the most
common non-haematological toxicity. Most of the non-
haematological toxicities were not life threatening and
were tolerated by the patients. The toxicities experienced
by the patients are presented in Table 4.
Discussion
MVAC elicited a significant response rate in GP-failed
patients with advanced urothelial cancer in the current
study, which is consistent with the results reported in
previous studies using MVAC in the second-line setting.
Since Han et al. reported the efficacy and toxicity of
MVAC as a second-line chemotherapy, [13] several
additional studies have assessed the efficacy of this
second-line treatment regimen [10–12]. The current study
Table 1 Patient characteristics
Sex Patients (%)
Female 0 (0.0 %)
Male 45 (100 %)
Age, median (year, range) 65 (60–72)
Primary tumor site
Bladder 30 (66.7 %)
Ureter or renal pelvic 6 (13.3 %)
Ureter or renal pelvic with bladder 9 (20.0 %)
Nodal status
N0 6 (13.3 %)
N1 8 (17.8 %)
N2 19 (42.2 %)
N3 12 (26.7 %)
Distant metastatic site at the time of MVAC administration
Lung 21 (46.7 %)
Bone 16 (35.6 %)
Liver 9 (20.0 %)
Other 4 (8.9 %)
Absence 16 (35.6 %)
Single 13 (28.9 %)
Multiple 16 (35.6 %)
ECOG performance status (PS)
PS 0 20 (44.4 %)
PS 1 23 (51.1 %)
PS 2 2 (4.4 %)
MVAC methotrexate vinblastine Adriamycin cisplatin, ECOG Easton Cooperative
Oncologic Group
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demonstrated that MVAC resulted in a significantly
higher response rate and longer PFS after the failure of
GP in patients with advanced UC who responded to GP
as the first-line chemotherapy compared with non-
responders. The response rate and median PFS of patients
administered second-line MVAC after GP was 77 % and
8.0 months in responders compared with 40 % and
3.7 months in non-responders, respectively. This suggests
that re-challenge using a platinum-based regimen could
induce a high response rate and durable PFS after the
initial failure of first-line platinum-based chemotherapy
in patients with advanced UC. In addition, a higher re-
sponse rate and longer PFS could be achieved by pa-
tient selection.
Table 2 Comparison of several factors for patients who were divided by the response to first-line GP chemotherapy
Good (n = 30) Poor (n = 15) P
Age, median (year, range) 64.0 (58.5–73.0) 66.0 (64.0–71.0) 0.289
Type of platinum compound used as the first-line 0.695
Cisplatin 23 (76.7 %) 13 (86.7 %)
Carboplatin 7 (23.3 %) 2 (13.3 %)
Response to the first-line GP chemotherapy -
CR 11 (36.7 %) -
PR 19 (63.3 %) -
SD - 5 (33.3 %)
PD - 10 (66.6 %)
TTP of the first-line GP chemotherapy, median (months, range) 11.6 (7.8–14.2) 3.13 (2.2–5.0) <0.001
Cycles of the first-line GP chemotherapy, median (range) 6.0 (6.0–7.3) 4.0 (3.0–4.0) <0.001
TFI between GP and MVAC, median (months, range) 2.5 (0.7–9.9) 1.7 (0.6–3.4) 0.202
Primary tumor site >0.999
Bladder 20 (66.7 %) 10 (66.7 %)
Ureter or renal pelvic 4 (13.3 %) 2 (13.3 %)
Ureter or renal pelvic with bladder 6 (20.0 %) 3 (20.0 %)
Clinical N stage 0.453
N0 4 (13.3 %) 2 (13.3 %)
N1 5 (16.7 %) 3 (20.0 %)
N2 11 (36.7 %) 8 (53.3 %)
N3 10 (33.3 %) 2 (13.3 %)
Distant metastatic site at the time of MVAC administration
Lung 15 (50.0 %) 6 (40.0 %) 0.752
Bone 10 (33.3 %) 6 (40.0 %) 0.746
Liver 8 (26.7 %) 1 (6.7 %) 0.234
Others 4 (13.3 %) - (0.0 %) 0.285
Hemoglobin (g/dL, range) 11.3 (10.5–11.9) 11.0 (9.8–11.3) 0.032
Absolute neutrophil count (/dL, range) 3751.5 (2733.0–5337.0) 3524.0 (2415.0–5252.0) 0.596
Platelet count, 103(/dL, range) 219.5 (184.8–291.5) 216.0 (169.0–311.0) 0.952
eGFR (ml/min, range) 62.6 (52.6–75.3) 71.5 (47.0–84.7) 0.739
Serum bilirubin (mg/dL, range) 0.4 (0.3–0.6) 0.3 (0.3–0.4) 0.047
Serum albumin (g/dL, range) 4.0 (3.8–4.4) 3.8 (3.5–4.2) 0.159
ECOG performance status (PS) 0.275
PS 0 12 (40.0 %) 8 (53.3 %)
PS 1 16 (53.3 %) 7 (46.7 %)
PS 2 2 (6.7 %) - (0.0 %)
GP gemcitabine platinum, CR complete response, PR partial response, SD stable disease, PD progression disease, TTP time to progression, TFI treatment free interval,
MVAC methotrexate vinblastine Adriamycin cisplatin, eGFR estimated glomerular filtration rate, ECOG Easton Cooperative Oncologic Group, Boldface significant 2-tailed
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Several studies have reported efforts to find an effect-
ive chemotherapeutic regimen after the failure of
platinum-based chemotherapy for patients with meta-
static, recurrent and inoperable UC [16]. Among the
non-platinum-based combination regimens, paclitaxel
and gemcitabine have achieved the greatest response
rate and PFS of the regimens tested to date in a phase 2
study [17]. Paclitaxel and gemcitabine chemotherapy
yielded a 60 % response rate and a 14.4-month median
OS. However, 25 of the 41 patients had been treated using
first-line platinum-based chemotherapy in a neo-adjuvant
or adjuvant setting, and the response rate was only 27 %
in the metastatic setting. Bellmunt et al., reported that
Vinflunine improved median PFS and OS in a phase 3
study [18]. However, Vinflunine yield only and 8.6 %
response rate, and did not demonstrate fully satisfactory
survival benefits. Consequently, no satisfactory standard
therapy has been found in a second-line setting [19].
Several investigators have questioned whether failure
of one platinum-based chemotherapy means true resist-
ance to another platinum-based chemotherapy in UC
patients, because different combinations of chemothera-
peutic agents exert different synergistic effects on cancer
cells, even if they are all based on platinum [10–13, 20].
Edeline et al. and Karadimou et al. suggested that
patients with a history of first-line GP chemotherapy in
an adjuvant setting and a relatively better ECOG
performance status had a more favourable response
after second-line MVAC chemotherapy [11, 12]. In
addition, Han et al. suggested that patients with a
complete or partial response to first-line platinum-based
chemotherapy were more likely to show a favourable re-
sponse to a second-line platinum-based chemotherapy
[13]. Gondo et al. also supported a relationship between
the responses to first-line and second-line platinum-based
chemotherapy in their study on the efficacy and safety of
GC as second-line chemotherapy after the failure of first-
line MVAC [20]. However, all these studies were limited
by a small sample size. The current study is the first to re-
port that the response to first-line GP is a statistically sig-
nificant predictive marker for response rate and PFS after
second-line MVAC, and it also demonstrates that proper
patient selection could achieve a higher response rate and
longer PFS in patients with advanced UC.
There are several possible explanations for the re-
response phenomenon to platinum-based chemotherapy
in patients who failed a first platinum-based chemother-
apy. Even after UC cells acquire platinum resistance and
the disease progresses, the cells might acquire total re-
sistance to gemcitabine but have incomplete resistance
to platinum. Several authors suggested that the synergic
effects of combination chemotherapy appear to be able
to overcome the resistance of first-line platinum-based
chemotherapy in ovarian and lung cancer [21–23].
Fig. 1 Kaplan-Meier curve for progression-free survival (%) in the good response and poor response groups. The good response group included
patients who achieved a complete or partial response to first-line GP chemotherapy, whereas the poor response group included individuals with
stable or progressive disease after first-line GP chemotherapy
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Combination therapy using more than two agents in-
duces synergistic anti-cancer effects, and different
combinations of chemotherapeutic agents can induce
different synergies. The MVAC regimen might in-
duce different synergistic effects from those of the
GP regimen in UC. Methotrexate, vinblastine and
Adriamycin might support the anti-cancer activity of
cisplatin differently from that of gemcitabine; there-
fore, these different effects can affect the response of
GP-failed patients to MVAC.
One of the problems with second-line treatment of ad-
vanced UC patients is that performance generally deteri-
orates after the failure of first-line chemotherapy due to
cancer progression, delayed recovery of marrow function
or decreased organ function. This limits the choice of
chemotherapeutic agents in the second-line setting, be-
cause the lack of response to second-line treatment can
be fatal if it results in further progression of metastases
and deterioration of general performance and organ func-
tion. Therefore, the appropriate selection of a second-line
therapeutic regimen is critical in patients with advanced
UC. Additionally, patients receiving MVAC chemotherapy
could experience a variety of complications. Several stud-
ies have reported MVAC chemotherapy-based toxicities
[24–28]. Haematological toxicities developed in ~70 % of
the patients in the current study, and many different non-
Table 3 Predictors of progression-free survival
Variables HR 95 % CI P
Univariate analysis
Age 1.046 1.004–1.089 0.031
Type of platinum compound used as the first-line (cisplatin vs carboplatin) 1.670 0.750–3.718 0.209
TTP of the first-line GP chemotherapy 0.951 0.885–1.022 0.175
Cycles of the first-line GP chemotherapy 0.947 0.834–1.076 0.404
TFI between GP and MVAC 0.991 0.943–1.042 0.735
Primary tumor site
Bladder vs ureter or renal pelvis/ ureter or renal pelvis with bladder 1.525 0.782–2.975 0.216
Bladder/ ureter or renal pelvis vs ureter or renal pelvis with bladder 1.735 0.806–3.733 0.159
Nodal status
N (0 vs 1,2,3) 1.074 0.413–2.789 1.074
N (0,1 vs 2,3) 0.712 0.354–1.431 0.340
N (0,1,2 vs 3) 0.541 0.246–1.193 0.128
Metastatic site
M0 vs M1 1.335 0.670–2.658 0.411
Lung 1.502 0.798–2.872 0.207
Bone 1.207 0.631–2.310 0.569
Liver 1.854 0.862–3.987 0.114
Others 1.056 0.371–3.007 0.919
Multi-organ metastasis (absence vs presence) 1.696 0.874–3.294 0.118
Hemoglobin 0.846 0.661–1.082 0.182
Absolute neutrophil count 1.000 1.000–1.000 0.823
Platelet count 1.001 0.997–1.004 1.001
eGFR 1.000 0.979–1.021 0.989
Serum bilirubin 0.529 0.077–3.630 0.517
Serum albumin 0.417 0.161–1.078 0.071
ECOG performance status (0 vs 1,2) 1.333 0.699–2.543 0.382
Response to first-line GP 2.520 1.245–5.015 0.010
Multivariate
Age 1.047 1.004–1.093 0.033
Response to first-line GP 2.500 1.228–5.098 0.012
HR hazard ratio, CI confidence interval, TTP time to progression, GP gemcitabine platinum, TFI treatment free interval, MVAC methotrexate vinblastine Adriamycin
cisplatin, eGFR estimated glomerular filtration rate, ECOG Easton Cooperative Oncologic Group, Boldface significant 2-tailed
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haematological toxicities also occurred. Because these
complications can be life threatening, the use of second-
line MVAC chemotherapy should be considered carefully
and used only in patients who can benefit from this ap-
proach. Therefore, accurately predicting patients who will
have a favourable response to second-line MVAC chemo-
therapy is critical.
The main strength of the current study was the identi-
fication of independent predictors of PFS in patients
who received second-line MVAC chemotherapy, even
though the results might have been affected by the retro-
spective nature of the study and the small number of pa-
tients included in the analysis. These results need to be
confirmed and validated by analysing data from a larger
prospective study.
Conclusions
The response to first-line GP is an important predictive
and prognostic factor for second-line MVAC in patients
with advanced UC. MVAC chemotherapy should be
considered as second-line treatment for advanced UC
patients who originally responded to GP.
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